BCL2L1 and ovarian carcinoma: This conclusion was further supported by the evidence that combination of GNE-493 and A-1155463 led to significant sensitization of the ovarian cancer cells, with up to 98–99% inhibition for the most sensitive models (Fig. 6c, Supplementary Fig. 8A) and the potency of this combination was predicted by BCL-XL protein levels (Supplementary Fig. 8B).